LOGAN, UT and CINCINNATI, OH, April 7, 2026 – IBEX Preclinical Research, a leading med tech CRO for preclinical surgical studies across a variety of laboratory animal species, and Sus Clinicals, a pioneering provider of genetically-modified large animal models for cancer, announced today a collaborative relationship to better serve the medical device industry and accelerate their clients’ most promising oncologic innovations.
Melissa Bruns, AAS, Business Development Manager at IBEX, said: “We couldn’t be more pleased to be working with Sus Clinicals. Having access to their inducible transgenic large animal platform will extend the research services we can provide our clients. With Sus Clinicals’ Oncopig ® capable of generating human-like tumors on demand, we can provide a testing platform to accelerate development of interventional and minimally invasive devices, as well as even more clinically-relevant physician training services.”
Jessicca Rege, Ph.D., Chief Executive Officer of Sus Clinicals, said: “We are delighted to be working with the talented team at IBEX. Their demonstrated commitment to serving the med tech industry, helping researchers accelerate device development, makes them a terrific partner for us.”
IBEX’s focus on serving the medical device industry with a range of preclinical research services, combined with Sus Clinicals’ proprietary Oncopig inducible tumor platform, will support medical device companies’ efforts to accelerate their most promising oncology treatments and tools into the clinic, helping to save lives.
About IBEX:
Founded in 2003, IBEX Preclinical Research, Inc. is a trusted outsourced partner and provider of preclinical surgical studies in a variety of laboratory animal species. By focusing on their core values of quality research and superior client service, IBEX has grown into a research leader in experimental surgical studies including orthopedics, soft tissue and vascular surgery. IBEX also provides non-surgical studies such as drug toxicity and pharmacokinetics. IBEX recently completed a second facility expansion to meet the increasing demand from clients, and is currently in the planning process for a third facility expansion.
About Sus Clinicals:
Sus Clinicals accelerates the qualification of potentially life-saving cancer therapeutics through its proprietary Oncopig® platform. In collaboration with top CROs and research institutions with large animal testing capability, Sus Clinicals’ predictive model better identifies drugs, diagnostics, and devices with the highest potential for success in human clinical trials. Sus Clinicals is headquartered in Cincinnati, with its scientific team based in Chicago.
